Compare Natera Inc. Common Stock (NTRA) vs Roku Inc. Class A Common Stock (ROKU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Roku Inc. Class A Common Stock — how do they compare? Natera Inc. Common Stock trades at $394.6 (market cap $57.03B), while Roku Inc. Class A Common Stock trades at $152.43 (market cap $22.67B). The key difference: Natera Inc. Common Stock is far larger — about 2.5× Roku Inc. Class A Common Stock's market cap, and Natera Inc. Common Stock is more actively traded (1,131,157 versus 1,039,228). Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Roku Inc. Class A Common Stock for 6 Days on average.
| NTRA | ROKU | |
|---|---|---|
Market Cap | $57.03B | $22.67B |
Volume | 1,131,157 | 1,039,228 |
Sector | Health | Media |
52-Week High | $425.64 | $159.76 |
52-Week Low | $179.42 | $82.93 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $56.18B | $20.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Roku trades at $152.66, down slightly by 0.1% today. The stock shows mixed technical signals with a neutral overall rating. Fundamentally, revenue growth is solid with 2026 projections at $5.2B, while profitability improved significantly with net income margin rising to 6.81%. Recent earnings beats and the pending Fox acquisition approval highlight positive momentum. Analyst consensus is evenly split between Buy and Hold with a $161.38 price target.
Outlook remains cautiously optimistic with strong earnings performance and acquisition synergies offering upside potential. Key risks include regulatory scrutiny of the Fox deal, competitive pressures in streaming, and negative cash flow trends. The stock presents a growth opportunity if execution continues, but investors should monitor acquisition progress and profitability sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Roku Inc. Class A Common Stock
Roku operates a streaming platform that combines its operating system, streaming devices, TV partnerships, and advertising services. It connects viewers with streaming content and services.
Read more on ROKU →
